Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

Barrett JR., Belij-Rammerstorfer S., Dold C., Ewer KJ., Folegatti PM., Gilbride C., Halkerston R., Hill J., Jenkin D., Stockdale L., Verheul MK., Aley PK., Angus B., Bellamy D., Berrie E., Bibi S., Bittaye M., Carroll MW., Cavell B., Clutterbuck EA., Edwards N., Flaxman A., Fuskova M., Gorringe A., Hallis B., Kerridge S., Lawrie AM., Linder A., Liu X., Madhavan M., Makinson R., Mellors J., Minassian A., Moore M., Mujadidi Y., Plested E., Poulton I., Ramasamy MN., Robinson H., Rollier CS., Song R., Snape MD., Tarrant R., Taylor S., Thomas KM., Voysey M., Watson MEE., Wright D., Douglas AD., Green CM., Hill AVS., Lambe T., Gilbert S., Pollard AJ., Oxford COVID Vaccine Trial Group None.

DOI

10.1038/s41591-021-01372-z

Type

Journal article

Journal

Nat Med

Publication Date

06/2021

Volume

27

Permalink Original publication